Monofer (Ferric Derisomaltose)

Ferric derisomaltose is a stable iron‑carbohydrate complex that releases elemental iron after intravenous infusion. The iron is captured by reticulo‑endothelial cells, bound to transferrin, and incorporated into hemoglobin and myoglobin, thereby restoring depleted iron stores and supporting red blood cell production.

The dose of Monofer is individualized by the prescribing clinician based on the patient’s iron deficit, body weight, and clinical condition. The prescriber calculates the required iron amount and selects an appropriate infusion volume and rate according to the product’s prescribing information.

Safety data for Monofer in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To order Monofer, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and import documentation.

Monofer delivers a larger single‑dose of elemental iron compared with iron sucrose, allowing faster repletion with fewer infusions. Compared with ferric carboxymaltose, it has a similar safety profile but differs in carbohydrate shell composition, which may affect tolerability in some patients.

Monofer should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze the solution or shake the vial vigorously. Keep the product in its original packaging until ready for use to maintain stability.

Monofer is given as an intravenous infusion. The vial is diluted with the appropriate diluent as described in the prescribing information, then infused over the recommended time period, typically ranging from 15 to 30 minutes, while the patient is monitored for adverse reactions.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, marked hypotension during or after infusion, and iron overload leading to organ toxicity. Prompt recognition and management of these events are essential.

Monofer should be avoided in patients with known hypersensitivity to ferric derisomaltose or any component of the formulation, in those with active severe infections, and in individuals with uncontrolled hypertension or severe renal impairment unless closely monitored by a specialist.